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Epigenetics is essentially a phenotypical change in gene expression without any alteration
of the DNA sequence; the emergence of epigenetics in cancer research and mainstream
oncology is fueling new hope. However, it is not yet known whether this knowledge will
translate to improved clinical management of ovarian cancer. In this malignancy, women
are still undergoing chemotherapy similar to what was approved in 1978, which to this day
represents one of the biggest breakthroughs for treating ovarian cancer. Although liquid
tumors are benefiting from epigenetically related therapies, solid tumors like ovarian can-
cer are not (yet?). Herein, we will review the science of molecular epigenetics, especially
DNA methylation, histone modifications and microRNA, but also include transcription fac-
tors since they, too, are important in ovarian cancer. Pre-clinical and clinical research on the
role of epigenetic modifications is also summarized. Unfortunately, ovarian cancer remains
an idiopathic disease, for the most part, and there are many areas of patient manage-
ment, which could benefit from improved technology. This review will also highlight the
evidence suggesting that epigenetics may have pre-clinical utility in pharmacology and
clinical applications for prognosis and diagnosis. Finally, drugs currently in clinical trials
(i.e., histone deacetylase inhibitors) are discussed along with the promise for epigenetics
in the exploitation of chemoresistance. Whether epigenetics will ultimately be the answer
to better management in ovarian cancer is currently unknown; but we hope so in the future.
Keywords: microRNA, ovarian cancer, epigenetics, DNA methylation, histone modifications
INTRODUCTION TO EPIGENETIC MODIFICATIONS
Although genetic alterations, such as gene copy-number varia-
tions, contribute to the development of cancer, classical genetics
alone does not account for all acquired characteristics of cancer
cells. For this reason, it is generally appreciated that epigenetic
abnormalities are involved in tumorigenesis. The definition of
epigenetics is the potentially permanent and heritable change in
gene expression, which is not attributed to any alteration in the
underlying DNA sequence, but results from structural adaptations
and responsive outcomes on chromosome regions (1, 2). Epige-
netic modifications among cancer cells result in aberrant gene
expression via DNA methylation, histone modifications, and non-
coding microRNAs (miRNAs) and can also include alterations
among transcription factors (3), although the latter is less often
emphasized in epigenetics. These modifications are associated
with initiation and progression of ovarian cancers (Figure 1).
DNA methylation is the most frequently studied epigenetic
phenomenon. DNA methylation occurs among cytosine residues
in cytosine–guanine (CpG) dinucleotides, which are mostly dis-
tributed in the CpG-rich regions referred to as “CpG islands” (4).
This type of methylation is achieved by DNA methyltransferases
(DNMTs), which are a family of enzymes that serve to transfer
methyl groups onto DNA (5). In humans, DNMTs are divided
into two groups: DNMT1 and DNMT3.
Changes in DNA methylation regulating gene expression are
widespread, appearing in both normal and cancerous cells. For
example, roughly 80% of CpG dinucleotides in the human genome
are subject to methylation changes throughout life. In addition,
nearly 70% of all CpG islands are methylated at any given time
(6). Furthermore, in normal cells, DNA methylation regulates the
silenced allele of imprinted genes and also represses expression
of potentially harmful DNA transposon sequences (7). Interest-
ingly, alterations and deregulation of epigenetic events precede
the transformation that generates cancer cells (8).
EPIGENETIC MODIFICATIONS IN CANCER
Among cancer cells, DNA hyper-methylation is associated with
gene silencing and DNA hypo-methylation with gene expres-
sion, both of which are widespread characteristics of malig-
nancy (Figure 2). Most often, hypermethylated CpG islands
within the DNA silence critical tumor suppressor genes, wreck-
ing havoc on the cell’s ability to repair DNA damage, control
cell growth, and inhibit proliferation. On the other hand, DNA
hypo-methylation contributes to oncogenesis when previously
silenced oncogenes become transcriptionally activated. In addi-
tion, DNA hypo-methylation can activate latent transposons and
cause chromosomal instability in specific pericentromeric satellite
regions (9–14).
Histone modifications also play important roles in epigenetic
regulation. Histones are dynamic proteins that can become methy-
lated or acetylated on specific amino acid residues, which corre-
lates with active or repressive transcription (15, 16). An octamer
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FIGURE 1 | Outline of the functional effect resulting from specific epigenetic modifications in malignancy.
FIGURE 2 | Location of molecular epigenetic mechanisms dynamically affecting gene expression.
of histones make up the nucleosome, which is the fundamen-
tal building-block unit of chromatin. The nucleosome contains
lysine-rich histone tails extending outward from the four con-
stituent core histone proteins (H2A, H2B, H3, and H4). These
histone tails provide sites for reversible modifications to alter chro-
matin structure and thus, gene expression. By tightly winding and
condensing chromatin or loosening up the structure of chromatin,
transcription factors and other proteins are prevented or permit-
ted access to the DNA for transcription, respectively. The target
residues of histone modifications are lysine (acetylation, methy-
lation, and ubiquitination), arginine (methylation), and serine
and threonine (phosphorylation). The crosstalk between histone
modifications is complicated and varied based on chromosomal
domains.
Overall, the combination of histone modifications contributes
largely to chromatin pattern and gene expression (17). In gen-
eral, histone acetylation adds more negative charges to positive
lysine, thus loosening the electrostatic interaction between his-
tones and the DNA backbone. For this reason, the condensa-
tion of chromatin is partially regulated by histone deacetylases
(HDAC), a class of deacetylating enzymes that remove acetyl
groups from lysine residues of histones, ultimately causing the
repression of gene expression (18, 19). If methylation also tar-
gets the same lysine residue, which means excluding acetyla-
tion, the histone methylation will have the opposite effect, com-
pared to acetylation, and repress gene expression. However, it
is not an all-encompassing rule for every single case. In fact,
the situation is much more intriguing. Indeed, methylation can
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block repressive factors and act as a transcription-facilitating
element (20).
The extent of methylation status (mono-, di-, and tri-
methylation) and other types of histone modifications (phospho-
rylation or ubiquitination) are involved in a network of sophisti-
cated crosstalk, determining chromatin condensation status (17).
Furthermore, histone H3 phosphorylation is also suggested to
interfere with the electrostatic interaction between histones and
the DNA backbone, thus favoring transcription factor-induced
gene expression (21). (Other types of histone modifications, such
as ubiquitination and SUMOylation, are not discussed in this
review.) To further convolute this process, evidence suggests that
regulating gene expression may occur through crosstalk between
histone modifications and DNA methylations (22–24).
MicroRNAs are small, non-coding RNAs, which are about
18–25 nucleotides in length. They negatively regulate gene expres-
sion through complementary binding to the 3′ UTR region in
the promoter of targeted mRNAs, leading to mRNA degradation
or translational repression, which is dependent on the level of
complementarities (25, 26). Because of their unique functions,
miRNAs regulate many biological changes and contribute to can-
cer progression. For instance, studies comparing miRNA profiles
between normal and cancerous specimens identified alterations
of multiple miRNA during cancer development and progression
(27, 28). MicroRNAs can have dual roles in cancer progression,
as tumor suppressors that repress oncogenes or as tumorigenesis
factors that deregulate tumor suppressor genes (29).
EPIGENETIC CHANGES IN OVARIAN CANCER
Role of DNA methylation in the development of malignancy
As previously stated, DNA methylation can prevent the transcrip-
tion of tumor suppressor genes. Examples of this occurrence in
ovarian cancer include the human MutL homolog 1 (hMLH1) and
breast cancer susceptibility gene 1 (BRCA1), which are two criti-
cal genes that transcribe proteins involved in the DNA damage
response and DNA mismatch repair. These processes are critical in
maintaining a stable chromosome and fixing damage. In ovarian
cancer, the promoter regions of genes encoding these two pro-
teins are hypermethylated, leading to the low expression levels of
hMLH1 and BRCA1 (30, 31). Indeed, women with genetic muta-
tions in BRCA1/2 are susceptible to breast, ovarian, and (some-
times) pancreatic cancer (32) due to this aberration. Among older
women with ovarian cancer, tumors are hypermethylated, leading
to suppression in transforming growth factor (TGF)-beta path-
way activity (33). Other silenced genes in ovarian cancer include
Ras-association domain gene family 1A (RASSF1A), lost on trans-
formation 1 (LOT1), death-associated protein kinase (DAPK),
target of methylation-induced silencing (TMS1)/apoptosis speck-
like protein containing a CARD (ASC) (34–37), and insulin-like
growth factor binding protein (IGFBP-3) (38). These genes encode
proteins involved in regulation of the cell cycle and the promotion
of apoptosis, which are important to maintain homeostasis.
Role of histone modifications in malignant tumorigenesis
Carcinogenesis and tumorigenesis are multifaceted; how normal
tissue precisely undergoes stepwise changes to yield ovarian cancer
and then how that progresses unregulated by mechanistic controls
is largely debated. However, many aspects involved in the pro-
gression of ovarian malignancy are reported, including the role
of histones in this process. For example, normal epithelial ovar-
ian cells repress the expression of claudin-3 and claudin-4, yet
these proteins are highly overexpressed in ovarian cancer. For
claudin-3, this change is exclusively attributed to repressive histone
marks, whereas claudin-4 repression occurs through histone mod-
ifications and DNA methylation (39). These findings explain the
molecular mechanisms of repressive histone marks likely occur-
ring during tumorigenesis; the rationale is that claudins are critical
components of tight junctions and other claudin family members
comprise gene signatures leading to worsened outcomes in ovarian
cancer (40).
Another example of histone modifications affecting cell–cell
interactions occurs in the TGF-beta1 receptor. This receptor is an
important regulator of cell growth, cell cycle, and it also activates
SMAD transcription factors. Interestingly, aberrant signaling of
TGF-beta1 receptor results in histone modifications and repres-
sive chromatin in ovarian cancer, which prevents the expression
of ADAM19, the protein containing A Disintegrin and A Metallo-
protease (41). ADAM19 is a metalloproteinase involved in cell–cell
interactions and cell adhesion. Taken together, these studies sug-
gest that histone modifications may be important epigenetic events
allowing cells to alter contact with their environment.
MicroRNA alterations in the malignant progression of ovarian
cancer
In ovarian cancer, miRNAs play a role in malignant progression.
Evidence of this comes from reports that 37.1% of the miRNA
genomic loci exhibit alterations in DNA copy-number (42). Other
molecular mechanisms of miRNA deregulation include DNA
methylation and histone modification of miRNA genes (43). Many
profiling studies performed in ovarian cancer models illuminate
abundant alterations. The results show that the miR-200 family
and let-7 family are aberrantly regulated (Table 1) along with
deregulated tumor suppressor miRNAs: miR-15a, miR-34a, and
miR-34b (43, 44).
In addition to genetically related explanations for miRNA
deregulation, there are also changes in regulatory proteins that
affect miRNA processing machinery. For example, there is a
Table 1 | Alterations in multiple miRNAs among ovarian cancer.
Type of cancer Up-regulated Down-regulated Target Reference
Ovarian cancer miR-200 family
(miR-200a,
miR-200b,
miR-200c,
miR-141,
miR-429),
miR-214,
miR-21,
miR-141,
miR-221,
miR-146b,
miR-508
miR-199a,
miR-140,
miR-145,
miR-125b1,
miR-100, let-7b,
miR-125b, let-7f,
miR-106b,
miR-134,
miR-155,
miR-346,
miR-424
(45–48)
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reduction in the protein expression levels of Dicer and Drosha.
These two proteins are essential factors involved in the biogenesis
of miRNAs (49). A loss of one dicer allele facilitates tumorigenesis
while a loss of both alleles in lethal to the cell (50). Furthermore,
low expression levels of Dicer and Drosha correlates with poor
clinical outcomes (49).
Significant interplay is likely between miRNAs and other mol-
ecular epigenetic mechanisms of DNA methylation and histone
modifications. For instance, let-7a-3 is hypermethylated in ovarian
tumor samples, and the suppression of this miRNA correlates with
good prognosis (51). As another example, the down-regulation of
miR-101 will de-repress its target EZH2, which is a catalytic sub-
unit of the polycomb repression complex 2 (PRC2). Because the
complex tri-methylates histone H3 lysine 27, its restoration aber-
rantly silences multiple tumor suppression genes in cancer (45,
52, 53). MiR-140, which targets histone deacetylase 4 (HDAC4), is
also reported to be down-regulated in ovarian cancer (45, 54).
EMERGING POTENTIAL OF EPIGENETICS IN THE DIAGNOSIS
OR PROGNOSIS OF OVARIAN CANCER
DNA METHYLATION TECHNIQUES IN OVARIAN CANCER DIAGNOSTICS
AND PROGNOSTICS
Analysis of DNA methylation status among tumor specimens is
the most favored approach for developing a biomarker diagnos-
tic/prognostic due to methylation stability, amplification ability,
high-sensitivity, and relatively low cost. In fact, DNA methylation
has demonstrated diagnostic and prognostic use in other types of
cancers, in particular glioma (55). To detect DNA methylation,
the simplest approach is to treat cells with DNA methyltransferase
inhibitors (DNMTIs). The treatment will reverse the DNA methy-
lation and result in re-expression of genes that were silenced by this
mechanism. Comparison of mRNA expression levels before and
after treatment will suggest candidates of methylation in cancer,
which can be confirmed using additional methods. An alternative
approach uses HpaII, a methylation-sensitive restriction enzyme
to digest genomic DNA samples prior to the amplification of
digested DNA (using PCR) to compare differences in methyla-
tion levels between samples (56). In a more straightforward way,
another method uses an antibody against 5-methylcytosine to pre-
cipitate methylated DNA fragments (DNA immunoprecipitation
or MetDIP) (57). Collected genomic DNA fragments are then
identified with array-based comparative genome hybridization to
reveal human methylome maps (58).
Despite their readiness, array-based DNA methylation analysis
approaches provide limited information about the extent and pat-
tern of methylation in specific CpG regions. To overcome this
drawback, bisulfite sequencing methods have been developed.
Bisulfite treatment converts unmethylated cytosine residues to
uracil, while methylated cytosine residues stay intact. After treat-
ment, specific primers are used in methylation-specific PCR to
amplify and help differentiate unmethylated and methylated DNA
regions (59). This method is used to identify the difference in DNA
methylation profiles in three major types of gynecological cancers:
ovarian, endometrial, and cervical cancers (60).
To date, multiple other techniques applying bisulfite treatment
have been introduced for whole-genome methylation sequenc-
ing and profiling. These include bisulfite padlock probes (BSPP),
solution hybrid selection bisulfite sequencing (SHBS-seq), array
capture bisulfite sequencing (ACBS-seq), and bisulfite-patch PCR
(61–66); comprehensive information on methylation profiling
is reviewed in Ref. (63, 67). In ovarian cancer, MethylCap-
Seq for whole-genome DNA methylation profiling is a method
using specific protein to capture methyl-CpG followed by high-
throughput sequencing. MethylCap-Seq has been applied to ana-
lyze methylomic patterns of ovarian tumors and results suggest
that hedgehog signaling pathway members (ZIC1 and ZIC4)
are DNA methylation prognostic biomarkers for ovarian can-
cer (68, 69).
A PROSPECTIVE OF HISTONE MODIFICATIONS IN PHARMACOLOGY
Although histone modifications lag behind DNA methylation in
this potential application, experimental data elude to future emer-
gence for this field. In support of this concept, research indicates
that the loss of H3 histone methylation correlates with significantly
reduced overall survival in ovarian cancer patients (70). In cell-
based assays, proteomic techniques have been applied to profile
expression-level changes, like histone modification enzymes, after
treatment with a heat shock protein 90 inhibitor (HSP90). Mal-
oney et al. suggested that similar analyses might aid pharmacology
by illuminating genes and proteins involved in drug responses
(71). Indeed, in ovarian cancer cells, histone de-acetylation at
the RGS10-1 promoter correlates with suppression of RGS10 and
chemoresistance (72). This data suggest the possibility of using
histone biomarkers to determine the appropriate selection of ther-
apeutics, particularly in cases of ovarian cancer chemoresistance,
moving toward “precision” medicine in the clinic (72, 73).
The growing list of experimental techniques to examine his-
tone modifications further alludes to emerging potential. The
traditional experimental techniques available include chromatin
immune precipitation (ChIP), which uses antibodies specific to
acetylated histone H3 and H4 to detect histone acetylation and
mass spectrometry-based proteomics to quantify histone mod-
ifications (74–78) and screen post-translational modifications
among enzymes involved in epigenetic processes, like DNMT and
HDAC (79). Other approaches are required to identify specific
DNA sequences paired with modified histones. In this regards, the
ChIP assay is coupled with a genomic tiling array (ChIP-chip) or
direct sequencing (ChIP-seq). In these techniques, DNA extracted
from ChIP is further processed to reveal the whole sequence,
allowing a detailed mapping of histone modifications affecting
the whole genome (80).
miRNA – A BIOMARKER FOR OVARIAN CANCER?
Regarding the diagnosis of ovarian cancer among unsuspecting
patients, there is no early detection biomarker that is used dur-
ing routine gynecological examinations of otherwise “healthy”
individuals. Although there are many candidates and extensive
ongoing research for biomarkers of early stage ovarian cancer,
biomarkers like CA-125 and CEA are limited to management of
confirmed cases. Since it is always desirable to detect malignancy
in the early stages with a minimally invasive method to collect
samples, the bar is set very high for this endeavor. In addition,
the accuracy requirement of a biomarker in a rare malignancy like
ovarian cancer is exceedingly challenging.
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In ovarian cancer, it is hypothesized that the detection of
miRNAs present in circulation may be able to meet this chal-
lenge. The rationale for miRNAs as favored candidate biomarkers
is due to the simplicity of obtaining blood samples and high-
sensitivity detection methods. In addition, miRNAs are found
in circulation within protected exosomes, which are small vesi-
cles released into the extracellular environment from many types
of cells, including tumor cells (81, 82). Interestingly, the trans-
fer of circulating miRNAs among cells is hypothesized to be a
method for internal communication within the body, similar to
hormones; thus, supporting the idea of a screening approach
involving miRNAs (82, 83).
There are many examples from the literature supporting the
concept of miRNA biomarkers for ovarian cancer. Studies show
that the expression levels of eight miRNAs have prognostic value in
ovarian cancer: miR-21, miR-141, miR-200a, miR-200b, miR-200c,
miR-203, miR-205, and miR-214 (45). Another study identified the
expression of 21 miRNAs significantly different between ovarian
cancer and normal serum specimens, including three known onco-
genic miRNAs (or “oncomirs”) with biomarker potential: miR-21,
miR-92, and miR-93 (84). Additionally, a large study using 300
plasma samples from ovarian cancer patients and 200 healthy con-
trols evaluated circulating miRNAs and concluded that these are
stable and specific. In this study, miR-205 and let-7f were signifi-
cantly reduced in cancer specimens compared to normal controls.
Moreover, let-7f has a lower expression level, which correlates
with poor prognosis (85). Finally, another study suggests that
among tumors, miR-9 and miR-223 deregulation is a biomarker
of recurrent ovarian cancer (86).
Since miRNAs are released by cells into exosomes, studies have
examined the viability of using exosomal miRNA as a poten-
tial biomarker. In this regard, research successfully used anti-
epithelial cell adhesion molecule (EpCAM) to isolate exosomes
secreted from ovarian tumors in plasma and compared exosome-
containing miRNA expression profiles between samples from
cancer patients versus healthy controls (87). Taylor and Gercel-
Taylor intriguingly demonstrated that the level of tumor-derived
circulating exosomes is higher in cancer patients than in nor-
mal controls. Furthermore, the level of increase correlates with
higher disease grade when the exosomes are presented as con-
centrated protein. Finally, this study also showed that miRNAs
profiles between cancer and benign specimens are significantly
different (87). Because of the laboratory success in using these
approaches, several groups have suggested the use of miRNAs
and/or exosomes as surrogate or complementary biomarkers for
biopsy profiling (85, 87, 88).
EPIGENETIC THERAPY IN OVARIAN CANCER
EXPLOITING DNA METHYLATION FOR THERAPEUTIC MANAGEMENT
Approaches to exploit DNA methylation changes for ovarian cancer
therapy
To reiterate, regions of the DNA experience changes in both hyper-
and hypo-methylation during cancer initiation and/or progres-
sion. In ovarian cancer, data suggest a correlation between global
and satellite DNA hypo-methylation with malignancy since an
overall increase in hypo-methylation is observed among ovar-
ian cancer tissues, in comparison with normal controls (89, 90).
Furthermore, the phenomenon of satellite DNA hypo-methylation
is an independent marker of poor prognosis (91).
Methylated genes are known in ovarian cancer and exhibit diag-
nostic potential. A study using methylation-specific PCR to screen
ovarian tumor samples for six tumor suppressor genes (BRCA1,
RASSF1A, APC, p14ARF, p16INK4a, and DAP-kinase) indicated
that this “hyper-methylation panel” provides diagnostic informa-
tion in ovarian cancer. In addition, this study further suggests that
the panel is 82% sensitive and 100% specific for the detection of
ovarian cancer using patient serum DNA in stage 1 (92).
The technology also holds potential use for ovarian cancer-
specific prognostic information. For example, methylation-
specific PCR analysis of tumor tissues from 270 patients identified
that IGFBP-3 gene promoter hyper-methylation is associated with
a higher risk of disease progression and mortality. Thus, hyper-
methylation of IGFBP-3 is hypothesized as a biomarker for ovarian
cancer outcomes, especially for patients in early stages of the
disease (93).
Due to the extensive aberrant DNA methylation in cancer
and the reversible nature of these events, inhibition of DNMTs
is a worthy therapeutic approach to re-express tumor suppres-
sors. DNMTIs are categorized into nucleoside and non-nucleoside
analogs based on their chemical structures and mechanisms of
action. DNMT nucleoside inhibitors incorporate into DNA, trap
and inactivate DNMTs in the form of a covalent-DNA adduct. On
the other hand, non-nucleoside DNMTIs directly block DNMT
activity without covalently trapping the enzyme, thus appearing
to have less toxicity (94). 5,6-Dihydro-5-azacytidine (DHAC) is
a nucleoside analog of DNMTI and is in clinical trials for the
treatment of ovarian cancer (95). Hydralazine, a vasodilator that
treats hypertension, is also a non-nucleoside DNMTI in clinical
trials for cervical cancer as both monotherapy and combination
therapy (96, 97).
Pre-clinical studies and clinical trials exploiting DNA methylation
for re-sensitization
Ovarian cancer is a treatment-intensive disease and clinics are most
often re-populated by their own patients. First-line chemother-
apy is initially very effective in the treatment of ovarian cancer
patients, but the period of remission they achieve is often short-
lived. Thus, many approaches seek to re-sensitize tumors to the
previously effective drugs. In contrast, others hypothesize that
because previous attempts to re-sensitize recurrent ovarian tumors
to first-line therapeutics has failed, they suggest that initial combi-
nations of compounds aimed at preventing chemoresistance is the
best approach (98). However, since neither approach has achieved
bona-fide, proof-of-principle, research into both approaches is
ongoing.
Researchers are evaluating the application of DNA methyla-
tion for chemotherapy re-sensitization. For example, the hyper-
methylation of hMLH1 (human MutL homolog 1) inhibits the
apoptotic response to platinum-DNA abduct formation from
platinum chemotherapy. Thus, this hyper-methylation is consid-
ered a major molecular cause of acquired resistance to platinum
chemotherapy in ovarian cancer (99). In addition, the presence
of methylated hMLH1 DNA in plasma after chemotherapy pre-
dicts poor survival for ovarian cancer patients (100). Interestingly,
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the hMLH1 activity is restored after treatment with 5-aza-2′-
deoxycytidine (decitabine) and so is the re-sensitization of ovarian
cancer to cisplatin (101).
Another example of DNA methylation and chemotherapy re-
sensitization surrounds RAS-associated domain family protein 1a
(RASSF1A). The promoter methylation of RASSF1A is highly
associated with ovarian cancer (34). RASSF1A binds to tubulin
and promotes microtubule polymerization and stabilization (102,
103). The presence of RASSF1A blocks genome instability induced
by RAS (85, 104). RASSF1A also causes cell cycle arrest through
blocking Cyclin D1 accumulation (105). For all these reasons,
RASSF1A is an interesting target for restoration.
Many pre-clinical studies present evidence that DNMT
inhibitors are efficient in de-repressing tumor suppressor genes.
This intimates that DNMT inhibitors may have therapeutic poten-
tial in combination regimens to overcome resistance and/or pro-
vide synergistic effects (106, 107). For example, decitabine re-
sensitizes chemoresistant ovarian tumor xenografts to cisplatin,
carboplatin, temozolomide, and epirubicin (101). Restoration of
RASFF1A by inhibiting DNMT also increases ovarian cancer cell
sensitivity to paclitaxel (108).
Indeed, DNMT inhibitors are also showing some success in
the clinic (Table 2). Decitabine is undergoing clinical trials with
carboplatin for patients with recurrent, platinum-resistant ovar-
ian cancer (109). A report of a phase II clinical trial of low-dose
decitabine combined with carboplatin for heavily treated and
platinum-resistant ovarian cancer patients showed positive results.
Low-dose decitabine altered the methylation of genes in tumorige-
nesis pathways, including the demethylation of hMLH1, RASSF1A,
HOXA10, and HOXA11, leading to re-sensitization to carbo-
platin, increased response rate, and prolonged progression-free
survival (110).
Hypo-methylation treatment, on the other hand, due to its
non-specific effects, can be detrimental. One known example is
the Fanconi anemia (FANC)–BRCA pathway in ovarian cancer.
The malfunction of genes in FANC pathway leads to devastating
mutagen hypersensitivity (111). In cancer treatment, the FNAC–
BRCA pathway plays a critical role in the response of cells to
DNA-crosslinking agents. However, it was observed that, in ovar-
ian cancer, FANC is inactivated due to hyper-methylation, and
the demethylation of FANC is associated with ovarian tumor
progression and acquired cisplatin resistance (112). In addition,
there are oncogenic genes overexpressed by hypo-methylation in
ovarian cancer, such as synuclein-γ and mammalian heparanase
(endo-beta-glucuronidase) (113–115).
Table 2 | Epigenetic drugs in gynecological cancer trials.
Drugs Other names Group Types of diseases
Valproic acid HDAC inhibitors Cervical, ovarian cancers
Belinostat HDAC inhibitors Gynecological cancers
Decitabine DNMT inhibitors Ovarian cancer
Hydralazine DNMT inhibitors Cervical cancer
Dihydro-5-
azacytidine
DHAC DNMT inhibitors Ovarian cancer
HISTONE MODIFICATIONS: HISTONE DEACETYLASE INHIBITION IN
CLINICAL TRIALS
Histone deacetylases are enzymes that remove acetyl groups and
have long been studied for treatment of cancer, in general, as well as
of gynecological cancers, specifically. Although HDAC overexpres-
sion occurs in many types of cancers (116, 117), siRNA silencing
HDAC1 and HDAC2 inhibits growth and promotes apoptosis in
ovarian and cervical cancer cells (118, 119). Similarly, HDAC6
facilitates oncogenic transformation in ovarian cancer (120). Thus,
there is sufficient support for the rational targeting and inhibiting
HDAC within the treatment of this malignancy.
Based on their chemical structures, HDAC inhibitors are
divided into four majors groups: short-chain fatty acid, hydrox-
amic acid, cyclic tetrapeptide, and benzamide (121). For example,
valproic acid, a reagent belonging to the short-chain fatty acid
group (also known as an anti-epileptic and mood stabilizer) is in
clinical trials for the treatment of cervical and ovarian cancers
(122–124). Scriptaid, another HDAC inhibitor in the hydrox-
amic group, showed growth inhibition and apoptosis-inducing
potential in ovarian and endometrial cancers (125). Apicidin, an
HDAC inhibitor in the cyclic tetrapeptide group, is also stud-
ied for its anti-growth effects in ovarian and endometrial cancer
cells (126).
The aberrant expression of HDACs in gynecological cancers is
likely associated with de novo resistance and/or poor chemother-
apeutic efficacy and thus, chemoresistance development. As with
nearly all new drugs, HDAC inhibitors are proposed for com-
bination therapy to strengthen therapeutic efficacy as well as to
minimize chemoresistance. Valproic acid has been studied in com-
bination with several cytotoxic drugs, such as methotrexate or
epirubicin, for synergistic or antagonistic effects in other types of
cancer (127, 128). Belinostat (PDX101), a novel HDAC inhibitor
in the hydroxamic acid group, displayed anticancer effects as a
single agent as well as in combination by increasing the acetyla-
tion of tubulin induced by docetaxel and the phosphorylation of
H2AX induced by carboplatin (129). Belinostat is under phase II
clinical trials for gynecological cancer treatment in combination
with platinum or paclitaxel to enhance effectiveness and help over-
come resistance (130–134). OSU-HDAC42 (or AR-42), another
new short-chain fatty acid HDAC inhibitor, has anti-growth effects
on ovarian cancer cells but not normal epithelial cells. The com-
pound re-sensitizes platinum-resisted ovarian tumors in vivo to
cisplatin and may have great potential for combinations with
platinum agents (135).
EXPLOITING miRNAs FOR RE-SENSITIZATION OF CHEMORESISTANT
DISEASE
The goal of targeting miRNAs in cancer treatment is to down-
regulate oncomirs, to inhibit mRNAs that will become onco-
genic proteins, or to restore tumor suppressor miRNAs. Multi-
ple techniques have been developed to target oncomirs, such as
locked nucleic acid (LNA), miRNA sponges, miRNA masking,
or small-molecule inhibitors (136–139). On the other hand, the
most straightforward way to restore tumor suppressor miRNAs
is to deliver pre-miRNA precursors or miRNA mimics. However,
straightforward it may appear, it is the targeted delivery of these
molecules that represents a major obstacle.
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A critical clinical problem in ovarian cancer is chemoresistance.
Multiple studies in the field have focused on the roles of miRNAs
in overcoming resistance to chemotherapeutic agents. Many miR-
NAs are reported as expressed differently between chemosensitive
and chemoresistant ovarian cell lines, such as miR-30c, miR-130a,
miR-335, among those, miR-130a is confirmed to target resistant
factor M-CSF (Table 3) (140). In addition, the enforced expression
of miR-30c-2-3p into chemoresistant and chemo-insensitive ovar-
ian cancer cells significantly reduces their viability, independently
of cisplatin or paclitaxel, without affecting immortalized ovarian
surface epithelial cells (141).
Although the miR-200 family is a potential prognostic fac-
tor of ovarian and endometrial cancer (87, 155), it may have
a role in re-sensitization. The low expression of miR-200c in
cancer leads to an increase in the expression of its target, class
III β-tubulin (TUBB3) (142). Since the expression of TUBB3
is required for chemoresistance to microtubule-binding agents
(e.g., taxanes and vinca alkaloids), restoration of miR-200c down-
regulates TUBB3, and effectively re-sensitizes ovarian cancer cells
to paclitaxel (142, 143, 156).
In addition to the miR-200 family, several members of the
let-7 family are well documented as down-regulated in ovarian
cancer, including let-7a, let-7b, let-7c, let-7d, and let-7i (44–
48, 144). Among these, let-7a is a potential biomarker for the
selection of chemotherapy in ovarian cancer. Patients with low
let-7 showed good response using platinum-paclitaxel combina-
tion therapy, while patients with higher let-7a had better survival
using platinum without paclitaxel; adding paclitaxel to this group
produced worse progression-free and overall survival (147). The
down-regulation of another member of the let-7 family, let-7i,
is associated with resistance of ovarian cancer cells to cisplatin,
which suggests that let-7i could be used as a therapeutic target
to overcome platinum resistance and as a biomarker to predict
chemotherapy response in ovarian cancer patients (144). Another
study observed that the let-7 family member, let-7g, down-
regulates the multiple drug resistance 1 (MDR1) gene, one of the
major factors causing paclitaxel resistance in ovarian cancer (145).
There are numerous other miRNAs that have roles in ovarian
cancer chemoresistance with known mechanisms. These include,
but are not limited to, miRNAs like miR-214, miR-27a, and miR-
451. MiR-214 targets PTEN, a known tumor suppressor, there-
fore, inducing cell survival and cisplatin resistance (46). MiR-27a
increases MDR1/P-glycoprotein expression in ovarian cancer cells
by targeting HIPK2 as an intermediate (157). Similarly, miR-451
and miR-21 also facilitate MDR1/P-glycoprotein overexpression,
leading to paclitaxel resistance in ovarian cancer cells (158, 159).
TARGETING TRANSCRIPTION FACTORS IN OVARIAN CANCER
Cancer is often a condition with aberrant gene expression, specif-
ically involving the overexpression of oncogenes. Altered tran-
scription factors are recognized as an epigenetic entity comprising
the “ovarian cancer cell epigenome” (3). This is not surprising
given the relationship between transcription factors and structural
(not sequence) alterations of the DNA (via DNA methylation and
histone modifications).
There are numerous examples of aberrant transcription factors
in cancer. Perhaps the most prominent of all is the tumor sup-
pressor protein p53. Mutations of TP53, the gene encoding p53,
are very common in ovarian cancer (160). In fact, nearly 100%
of patients with high-grade serous epithelial ovarian cancer have
Table 3 | miRNAs involved in chemoresistance.
miRNAs Trend in resistance Target genes Resisted drugs References
miR-200 family B-tubulin III TGF-beta2, ZEB1 Paclitaxel (142, 143)
Let-7i Reduced Cisplatin (144)
miR-30c, miR-130a, miR-335 Reduced M-CSF (target of miR-130a) Paclitaxel, cisplatin (140)
miR-214 Increased PTEN Cisplatin (46)
miR-27a, miR-21, miR-451 Increased MDR1 (indirectly through HIPK2,
in case of miR-27a)
Paclitaxel
Let-7g Reduced MDR1 (indirectly through IMP-1) Taxane agents (145)
miR-27a, miR-23a, miR-30c, let-7g,
miR-199a-3p, miR-378, miR-625
Increased Platinum agents (146)
Let-7a Caspase-3 Paclitaxel (147, 148)
miR-130b Decreased CSF-1 Cisplatin, paclitaxel (149)
miR-141 Increased KEAP1 Cisplatin (150)
miR-106a, miR-591 Increased (miR-106a) BCL-10, caspase-7, ZEB1 Paclitaxel (151)
Decreased (miR-591)
miR-29 Decreased COL1A1 Cisplatin (152)
miR-182 Increased PDCD4 TCEAL7 Paclitaxel (153, 154)
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mutations in p53. Overall, at least 50% of all ovarian tumors have
mutations in p53, most of which are point mutations leading to
amino acid substitutions. These are detrimental to the p53 protein
because they affect the DNA-binding domain of the transcription
factor (161). Unfortunately, therapeutic intervention using p53 as
the target molecule has not yet achieved measurable success (98).
The transcription factor and tumor suppressor protein p53 are
critical to the signaling pathways of cell cycle arrest and apopto-
sis. Once activated by DNA damage detection or UV radiation,
p53 induces the expression of many well-known apoptosis induc-
ers and other tumor suppressors, such as p21Cip1, BAX, PTEN,
and TSP-1. Because of this important role, the inactivation of p53
facilitates many phases of tumor progression as DNA damage can-
not be repaired and apoptotic pathways cannot be activated when
necessary (161).
Beside p53, other transcription factors have important roles in
ovarian cancer pathology. For example, Gil1 (glioma-associated
oncogene homolog 1) expression is elevated in advanced serous
ovarian cancer and this event is correlated with unfavorable
survival (162). Since transcription factor alterations can have a
tremendous impact on the balance of the entire biological sys-
tem, targeting transcription factors is an emerging trend in cancer
therapy research. The possibility of exerting broad control over
the system could be a powerful method of regaining regulatory
control. This is especially in light of lessons learned in other can-
cers whereby targeting one particular kinase or protein in a larger
signaling pathway leads to the rapid acquisition of therapeutic
resistance.
On the other hand, inhibiting particular transcription fac-
tors could provide specificity toward malignant overexpression
events in cancer (e.g., oncogenes, oncomirs, etc.). Furthermore,
this approach is appealing because it might produce more toler-
ance among healthy cells due to redundancies in normal signaling
pathways. Two major approaches in targeting transcription factors
are post-transcriptional silencing (using siRNAs or miRNAs) or
blocking the binding of transcription factors to DNA during acti-
vation. Another indirect approach is regulating histone-modified
enzymes and DNA methyltransferase if the target transcription
factor is mis-regulated through histone modification and/or DNA
methylation.
Many well-known transcription factors are studied as poten-
tial targets in general cancer treatment, such as STATs, NF-κB,
and Notch1 (163–165). In gynecological cancers, multiple studies
have reported the involvement of transcription factors in cancer
progression and described them as potential targets for cancer
treatment. In ovarian cancer, the blockage of STAT3 using a decoy
oligodeoxynucleotide inhibits cancer cell growth (166). Another
study in ovarian cancer also showed that suppression of NF-κB
activity using minocycline, a tetracycline, had beneficial effects
both in vitro and in vivo (167). More research is needed in this
area to refine this approach and evaluate its worthiness.
CONCLUSION: EPIGENETIC THERAPY
By undertaking research projects focused on epigenetic-related
translational applications, are basic scientists investigating a ratio-
nal clinical promise? To address this question, it is necessary to
review the successful progression of ideas from the laboratory into
clinic therapeutics. Although no epigenetic drugs have advanced
into the clinic for use against ovarian cancer, there are sev-
eral FDA-approved therapeutics (e.g., vorinostat, decitabine, and
romidepsin) for other types of cancer, especially liquid tumors.
Clinical trials are ongoing for ovarian cancer with epigenetic
therapeutics (Table 2). Since first-line therapy often results in
disease remission, predictions support using new drugs in combi-
nation therapy. Although hope lingers for PARP inhibitors, this
class of drugs may only treat a specific population of women
(168). Whether using epigenetic modifiers will achieve significant
improvements in overall survival is incalculable. Nevertheless, to
advance patient outcomes in ovarian cancer, new approaches are
required – the previous breakthroughs occurred in 1978 (cisplatin)
and 1992 (paclitaxel). An improved therapeutic regimen for ovar-
ian cancer is long overdue. Epigenetics provide hope in a new
direction.
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